Establishment of JMML-derived iPS cells for evaluation of the effect for anti-tumor reagents

• Project/Area Number: 25860405
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Laboratory medicine
• Research Institution: Shinshu University
• Principal Investigator: MATSUDA Kazuyuki 信州大学, 医学部附属病院, 主任臨床検査技師 (00647084)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000); Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2013: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
• Keywords: 若年性骨髄単球性白血病 / iPS細胞 / センダイウィルス / 白血病治療薬スクリーニング

Outline of Final Research Achievements

We established the JMML-derived iPS cells using Sendai virus vector. CD34-positive cells were differentiated from the iPS cells co-cultured with AGM cells in the presence of cytokines (SCF, BMP4, TPO, and VEGF). And we demonstrated that Histone deacetylase inhibitor suppressed the growth of the CD34-positive cells. The patient-derived CD34-positive cells available constantly are useful to evaluate the effect for anti-tumor reagents.